UCL BioMedica

UCL Business (UCLB) is the technology commercialization company of University College London (UCL), responsible for managing the university's intellectual property and facilitating the translation of research into commercial products. Formed in 2006 through the merger of UCL BioMedica and the university's existing tech transfer activities, UCLB supports the creation of spin-out companies and licenses technologies to global pharmaceutical and biotech partners. The company has a particularly strong track record in advanced therapies, having played a pivotal role in the development of marketed products such as the gene therapy Roctavian and the CAR-T therapy AUCATZYL. UCLB operates as a wholly owned subsidiary of UCL, bridging the gap between academic innovation and the healthcare industry to deliver life-changing treatments to patients.